Conviction
$ Value
$500K
Shares
270,270
Price
$2
Filed
May 19
▶ Why this score? (6/10)
- ✓ Open market buy (+3)
- ✓ Trade value >= $250K (+1)
- ✓ 10%+ owner (+1)
- ✓ Not a 10b5-1 plan (+1)
Insider
Name
ACORN BIOVENTURES, L.P.
Title
—
CIK
0001766853
Roles
Transaction Details
Transaction Date
2025-05-15
Code
P
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
1,709,944
Footnotes
Shares held directly by Acorn Bioventures, L.P. ("Acorn"). Acorn Capital Advisors GP, LLC ("Acorn GP") is the general partner of Acorn. Anders Hove is the manager of Acorn GP. Each of Acorn GP and Mr. Hove disclaims beneficial ownership of disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. | Shares held directly by Acorn Bioventures 2, L.P. ("Acorn 2"). Acorn Capital Advisors GP 2, LLC ("Acorn GP 2") is the general partner of Acorn 2. Anders Hove is the manager of Acorn GP 2. Each of Acorn GP 2 and Mr. Hove disclaims beneficial ownership of disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Filing Info
ACORN BIOVENTURES, L.P.'s History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2025-05-15 | OKUR | ▲ | $500K |
| 2025-05-15 | OKUR | ▲ | $2.1M ★ |
Other Insiders at OKUR (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| Ratcliffe Liam | — | — | 2026-03-31 |
|
Saccomano Nicholas A
President and CEO
|
— | $357 | 2026-04-01 |
|
Leverone Jason A.
Chief Financial Officer
|
— | $1K | 2026-04-01 |
|
Agresta Samuel
Chief Medical Officer
|
— | — | 2026-04-01 |
|
Hartley Dylan
Chief Scientific Officer
|
— | — | 2026-04-01 |